Európska únia - chorvátčina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - psorijaza - imunosupresivi - treatment of moderate-to-severe plaque psoriasis in adults.

Európska únia - chorvátčina - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresivi - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Chorvátsko - chorvátčina - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

bayer d.o.o., radnička cesta 80, 10000 zagreb, hrvatska - toltrazuril - peroralna suspenzija - antiparazitik - goveda (telad na farmama mliječnih krava)

Chorvátsko - chorvátčina - HALMED (Agencija za lijekove i medicinske proizvode)

hameln pharma gmbh, inselstrasse 1, hameln, njemačka - natrijev deksametazonfosfat - otopina za injekciju - urbroj: 1 ml otopine sadrži 4 mg deksametazonfosfata (u obliku natrijevog deksametazonfosfata) 2 ml otopine sadrži 8 mg deksametazonfosfata (u obliku natrijevog deksametazonfosfata)

Európska únia - chorvátčina - EMA (European Medicines Agency)

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - imunosupresivi - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

Chorvátsko - chorvátčina - HALMED (Agencija za lijekove i medicinske proizvode)

tillomed pharma gmbh, mittelstrasse 5/5a, schonefeld, njemačka - mofetilmikofenolat - kapsula, tvrda - 250 mg - urbroj: svaka kapsula sadrži 250 mg mofetilmikofenolata

Európska únia - chorvátčina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Európska únia - chorvátčina - EMA (European Medicines Agency)

zoetis belgium - inaktivirani virus bolesti plavog jezika, serotip 8, soj btv-8 / bel2006 / 02 - immunologicals - stoka - active immunisation of cattle from three months of age for the prevention of viraemia caused by bluetongue virus, serotype 8.

Európska únia - chorvátčina - EMA (European Medicines Agency)

zoetis belgium sa - inaktivirani virus bolesti plavog jezika, serotip 1 - immunologicals - stoka - aktivna imunizacija stoke od 2½ mjeseca za prevenciju viremije uzrokovane virusom bolesti plavog jezika, serotip 1. početak imuniteta: 15 dana nakon završetka primarnog cijepljenja. trajanje imuniteta: 12 mjeseci.

Čierna Hora - chorvátčina - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

dio stranog druŠtva "sanofi - aventis" - podgorica - živi atenuirani bacili m. bovis, soj bcg - prašak za intravezikalni rastvor - 81 mg